Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

ImmunoCellular Therapeutics LTD: Thoughts on Managements Plan to Move ICT-107 into Phase 3 (IMUC, Neutral, $1.02)

Investment Overview

ImmunoCellular and its dendritic cell cancer vaccine ICT-107 were written off as failures in December of 2013 after it…
Read more…

ImmunoCellular Therapeutics Trading Opportunity (IMUC, Not rated, $1.19, Paid Subscribers)

ImmunoCellular Therapeutics just announced that an abstract describing the phase II trial of its dendritic cell-based cancer vaccine ICT-107 in…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, June 10, 2013

Introduction
This weeks edition of SmithOnStocks Opines includes brief comments on news concerning ImmunoCellular Therapeutics (IMUC) and Cadence (CADX), last week…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, June 2, 2013

Overview of This Week's Report
This week I published a major report on Alimera Sciences and pSivida which led to my…
Read more…